Zota Healthcare Quarterly Results for Trading Insights
In Sept 2025, Zota Healthcare (ZOTA) reported revenue ₹131 Cr and net profit ₹-16 Cr — revenue +92.6% YoY. Compare with ZOTA DCF valuation to assess whether the stock is under or overvalued.
ZOTA Quarterly Results — Revenue, Profit & EPS Highlights
Zota Healthcare latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit ZOTA share price screener.
- Revenue of ₹131 Cr in Sept 2025 (+33.7% vs Mar 2025, +92.6% vs Sept 2024)
- Net Profit of ₹-16 Cr in Sept 2025 (-23.1% vs Mar 2025, -33.3% vs Sept 2024)
- EBITDA of ₹8 Cr in Sept 2025 (+100.0% vs Mar 2025)
- Operating Margin of 5.0% in Sept 2025 (+2.0pp vs Mar 2025)
- Earnings Per Share of ₹-5.26 in Sept 2025 (-15.1% vs Mar 2025)
Zota Healthcare Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ZOTA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 131 | 98 | 105 | 145 | 68 | 33.7% | 92.6% |
| Net Profit (₹ Cr) | -16 | -13 | -14 | -30 | -12 | - | - |
| EBITDA (₹ Cr) | 8 | 4 | 5 | 1 | 0 | - | - |
| EPS (₹) | -5.26 | -4.57 | -4.92 | -9.44 | -4.57 | - | - |
| Operating Margin (%) | 5.0% | 3.0% | 4.0% | 0.0% | -1.0% | - | - |
ZOTA Share Price Trend — 1-Year Movement Across Quarterly Results
Zota Healthcare 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Zota Healthcare stock price data download to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ZOTA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Zota Healthcare latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores